Botulinum Toxin: Mechanisms of Action
Open Access
- 12 January 2005
- journal article
- review article
- Published by S. Karger AG in European Neurology
- Vol. 53 (1), 3-9
- https://doi.org/10.1159/000083259
Abstract
Botulinum toxin (BT) has been perceived as a lethal threat for many centuries. In the early 1980s, this perception completely changed when BT's therapeutic potential suddenly became apparent. We wish to give an overview over BT's mechanisms of action relevant for understanding its therapeutic use. BT's molecular mode of action includes extracellular binding to glycoprotein structures on cholinergic nerve terminals and intracellular blockade of the acetylcholine secretion. BT affects the spinal stretch reflex by blockade of intrafusal muscle fibres with consecutive reduction of Ia/II afferent signals and muscle tone without affecting muscle strength (reflex inhibition). This mechanism allows for antidystonic effects not only caused by target muscle paresis. BT also blocks efferent autonomic fibres to smooth muscles and to exocrine glands. Direct central nervous system effects are not observed, since BT does not cross the blood-brain barrier and since it is inactivated during its retrograde axonal transport. Indirect central nervous system effects include reflex inhibition, normalisation of reciprocal inhibition, intracortical inhibition and somatosensory evoked potentials. Reduction of formalin-induced pain suggests direct analgesic BT effects possibly mediated by blockade of substance P, glutamate and calcitonin gene-related peptide.Keywords
This publication has 26 references indexed in Scilit:
- Dysport produces intrinsically more swallowing problems than Botox: unexpected results from a conversion factor study in cervical dystoniaJournal of Neurology, Neurosurgery & Psychiatry, 2002
- Session 15: PharmacologyCephalalgia, 2000
- Mechanics of membrane fusionNature Structural & Molecular Biology, 1998
- Muscle afferent block for the treatment of oromandibular dystoniaMovement Disorders, 1998
- Botulinum toxin does not reverse the cortical dysfunction associated with writer's cramp. A PET studyBrain, 1997
- Muscle afferent block by intramuscular injection of lidocaine for the treatment of writer's crampMuscle & Nerve, 1995
- Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25Nature, 1993
- Distant effects of local injection of botulinum toxinMuscle & Nerve, 1987
- TLC immunostaining characterization of Clostridium botulinum type A neurotoxin binding to gangliosides and free fatty acidsFEBS Letters, 1986